AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03547180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
Study NCT03547180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Capnometry-Assisted Respiratory Training
Description: The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
Study NCT01646151 — intervention group
Intervention type: DRUG
Intervention: Bimatoprost
Description: Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
Study NCT03547180 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-vivo exposure
Description: In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
Study NCT03254004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
Study NCT03185767 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride infusion
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride infusion
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride infusion
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Study NCT00409799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-0401 (a new bone graft substitute)
Description: 1 time application
Study NCT00409799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I-0401 (a new bone graft substitute)
Description: 1 time application
Study NCT03682250 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Libre Pro
Description: A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
Study NCT01786278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
Study NCT01786278 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic stenting
Description: Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
Study NCT03682250 — intervention group
Intervention type: DEVICE
Intervention: Holter monitor
Description: A Holter monitor will be used to measure heart's activity
Study NCT02209246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Interference
Study NCT02894788 — intervention group
Intervention type: OTHER
Intervention: ICU admission
Study NCT02209246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Pain Behavior
Study NCT02209246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS CAT Physical Function
Study NCT02209246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MISS-21
Study NCT01431430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100 000 UI
Description: Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
Study NCT01431430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 12 000 UI
Description: Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
Study NCT02189434 — intervention group
Intervention type: OTHER
Intervention: Serum procalcitonin lab draws
Description: Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients.
Study NCT01089335 — intervention group
Intervention type: PROCEDURE
Intervention: Histological investigation of the SN
Description: 99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
Study NCT00494949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
Study NCT00494949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
Study NCT00930306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: 12 doses, Given as capsule, 2 mg \& 8 mg
Study NCT00930306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 2 doses, Given as Tablet, 2x50 mg
Study NCT00930306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: 2 doses, Given as Tablet, half of 500 mg
Study NCT00930306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Tablet, 20 mg
Description: 2 doses, Given as Tablet, 20 mg
Study NCT00930306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Tablet, 7.5 mg
Description: 2 doses, Given as Tablet, 7.5 mg
Study NCT00293397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads loaded with doxorubicin hydrochloride
Description: Doxorubicin eluting beads
Study NCT02311452 — intervention group
Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter (PICC)
Description: Post-discharge antibiotics delivered via a PICC line.
Study NCT02429089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients.
Study NCT02471586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by IVUS
Description: Imaging type
Study NCT03515733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet, identical appearance to experimental tablet
Study NCT00413127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo
Study NCT00413127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: administration of lidocaine intravenously or epidural or administration of placebo
Study NCT00413127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Administration of placebo i.v.
Study NCT00729495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: dose form
Study NCT04143321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
Study NCT04143321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
Study NCT00729495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose form
Study NCT02471586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by OCT
Description: Imaging type
Study NCT02471586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by Angiography
Description: Imaging type
Study NCT02996110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT02996110 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT02996110 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified Dose on Specified Days
Study NCT02996110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified Dose on Specified Days
Study NCT02996110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified Dose on Specified Days
Study NCT02996110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: Specified Dose on Specified Days
Study NCT01989936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Study NCT01989936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Study NCT01989936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Study NCT00218452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
Study NCT01879891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic
Description: Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
Study NCT00242944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Pitavastatin 4mg per day
Study NCT00242944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg per day
Study NCT00397449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)
Study NCT01008436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omni-stat Celox
Description: Topical administration of 6 gr of Omnistat Celox
Study NCT01787396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Study NCT01787396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Metformin)
Study NCT01787396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01787396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(Gemigliptin)
Study NCT01566149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI
Description: Two oral inhalations per dose
Study NCT01566149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI
Description: Two oral inhalations per dose
Study NCT03172754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor
Study NCT03172754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Tyrosine kinase inhibitor
Study NCT01008436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traditional surgical Hemostasis
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 25 ug
Description: EP-101 (25 ug ) Dose 1 administered once daily for 7 days
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 50 ug
Description: EP-101 (50 ug ) administered once daily for 7 days
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 100 ug
Description: EP-101 (100ug) administered once daily for 7 days
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EP-101
Description: Placebo EP-101 administered once daily for 7 days
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide via (Spiriva® Handihaler®)
Description: Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium bromide Inhalation Solution via Handihaler® DPI
Description: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
Study NCT01426009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 via nebulizer (eFlow®) 200 ug
Description: EP-101 (200) ug administered once daily for 7 days
Study NCT00965744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel sealing system LigaSure
Description: Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
Study NCT01938391 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stealth 360°® OAS
Description: Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
Study NCT00542373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo oral tissue collection
Study NCT00542373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Mouth tissue examined microscopically for cytologic features
Study NCT00542373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Procedure
Description: Undergo standard white light headlamp oral examination
Study NCT00542373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo widefield fluorescent and reflectance imaging
Study NCT00542373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: Undergo point fluorescent spectroscopy
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo HCT
Study NCT06002997 — intervention group
Intervention type: OTHER
Intervention: Pregnancy and/or delivery complications
Description: Analysis of post-delivery reports for pregnancy and/or delivery complications.
Study NCT06002997 — intervention group
Intervention type: OTHER
Intervention: Periodontal disease
Description: Measuring clinical periodontal parameters for assessing presence of periodontal disease.
Study NCT03267433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02875366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Study NCT02875366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03184766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
Study NCT05088798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoro Dopa PET/MRI Imaging
Description: The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
Study NCT00587275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: Oral, sachet, 2 grams daily for 4 weeks
Study NCT00587275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celphere CP-305
Description: Oral, sachet, 2 grams daily for 4 weeks
Study NCT04255212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue treatment
Description: Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
Study NCT04255212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechaninsms explanation
Description: Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
Study NCT04255212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
Study NCT03184766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
Description: 2 x 200 mg ibuprofen \& 30 mg pseudoephedrine